Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Ionis Pharmaceuticals Inc banner

Ionis Pharmaceuticals Inc
F:ISI

Watchlist Manager
Ionis Pharmaceuticals Inc Logo
Ionis Pharmaceuticals Inc
F:ISI
Watchlist
Price: 47.4 EUR -0.06%
Market Cap: €6.9B
Write Note Create Alert Ask AI

Wall St Price Targets

ISI Price Targets Summary
Ionis Pharmaceuticals Inc

Wall Street analysts forecast ISI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ISI is 79.81 EUR with a low forecast of 35.49 EUR and a high forecast of 104.27 EUR.

ISI Lowest Forecast
35.49 EUR
-25% Downside
ISI Average Forecast
79.81 EUR
68% Upside
ISI Highest Forecast
104.27 EUR
120% Upside
Lowest Forecast
Price Target
35.49 EUR
25% Downside
Average Forecast
Price Target
79.81 EUR
68% Upside
Highest Forecast
Price Target
104.27 EUR
120% Upside
Ionis Pharmaceuticals Inc Competitors:
Price Targets
INBK
First Internet Bancorp
5% Upside
B
BRI
Britania PCL
5% Upside
CNSP
CNS Pharmaceuticals Inc
102% Upside
NYXH
Nyxoah SA
310% Upside
INBK
First Internet Bancorp
5% Upside
B
BRI
Britania PCL
5% Upside
CNSP
CNS Pharmaceuticals Inc
102% Upside
NYXH
Nyxoah SA
310% Upside

Revenue
Forecast

19% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
5%
Average Beat
19% / Year
Past Growth
26% / Year
Estimated Growth
Estimates Accuracy
5%
Average Beat

Over the last 13 years, the compound annual growth rate for Revenue has been 19%. The projected CAGR for the next 8 years is 26%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
24% / Year
Estimated Growth
Estimates Accuracy
8%
Average Beat
N/A
Past Growth
24% / Year
Estimated Growth
Estimates Accuracy
8%
Average Beat

The compound annual growth rate for Gross Profit over the next 8 years is 24%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss

What are analyst estimates?

Continue ISI Research

Summary
ISI intrinsic value, competitors valuation, and company profile.
DCF Valuation
ISI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ISI stock valuation using valuation multiples.
Wall St Estimates
ISI price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ISI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Ionis Pharmaceuticals Inc listings:
NASDAQ • USD
IONS
 XBER • EUR
ISI
 XMUN • EUR
ISI
 SWB • EUR
ISI
 LSE • USD
0JDI
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ISI's stock price target?
Price Target
79.81 EUR

According to Wall Street analysts, the average 1-year price target for ISI is 79.81 EUR with a low forecast of 35.49 EUR and a high forecast of 104.27 EUR.

What is the Revenue forecast for Ionis Pharmaceuticals Inc?
Projected CAGR
26%

Over the last 13 years, the compound annual growth rate for Revenue has been 19%. The projected CAGR for the next 8 years is 26%.

What is the Gross Profit forecast for Ionis Pharmaceuticals Inc?
Projected CAGR
24%

The compound annual growth rate for Gross Profit over the next 8 years is 24%.

Back to Top
ALPHA SPREAD
Follow us
Join 348,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett